Dynavax Technologies | Umsatzkosten



Cost Of Sales Veränderung Datum
AbbVie USD 4B 394M 2025-03
Adma Biologics USD 54.22M 5.96M 2024-12
Amgen USD 2.6B 507M 2025-03
AstraZeneca USD 2.24B 484M 2025-03
Biogen USD 629.3M 45.8M 2025-03
BioMarin Pharmaceutical USD 151.56M 15.42M 2025-03
Bristol-Myers Squibb USD 3.03B 179M 2025-03
Dynavax Technologies USD 27.54M 14.13M 2025-03
Gilead Sciences USD 1.54B 41M 2025-03
Glaxosmithkline GBP 2.52B 199M 2024-12
Merck USD 2.76B 944M 2025-03
Neurocrine Biosciences USD 9.3M 1.3M 2024-12
Novartis USD 3.32B 90M 2024-12
Pfizer USD 2.59B 3.06B 2025-03
Regeneron Pharmaceuticals USD 265.5M 299.9M 2025-03
Roche Holding CHF 4.13B 393.5M 2024-12
Sarepta Therapeutics USD 137.56M 5.26M 2025-03
TG Therapeutics USD 15.4M 6.06M 2024-12
Vertex Pharmaceuticals USD 423.4M 30.8M 2024-12



Dynavax Technologies Umsatzkosten - Diese Werte, historische Daten, Prognosen, Statistiken, Diagramme und ökonomische Kalender - May 2025.